In the past six months, Azenta's stock has been impacted by several events. On May 5, 2026, the company reported a fiscal second-quarter 2026 net loss of $160.8 million, including a $149 million goodwill impairment in its Multiomics segment, and cut its full-year guidance, leading to a significant stock drop. On May 17, 2026, independent director William L. Cornog purchased 10,000 shares. On August 4, 2026, fiscal third-quarter 2026 results surpassed Wall Street expectations, with non-GAAP earnings of $0.16 per share and revenue of $161.17 million, attributed to increased demand. On August 22, 2026, John P. Marotta resigned as President and CEO, with Dr. Martin D. Madaus appointed interim, causing a 12% stock fall on August 24, 2026. On September 4, 2026, Azenta received full repayment of a $35 million vendor loan related to the B Medical Systems sale. On September 14, 2026, Olga Pirogova, SVP and Chief Human Resources Officer, was granted 15,272 restricted stock units. On October 2, 2026, the stock reached a 52-week high of $41.84, reflecting a 52% return over six months. On October 5, 2026, the company approved a Multiomics restructuring plan involving workforce reductions and the closure of three North American laboratory sites, expected to incur $11.0 million to $13.0 million in pre-tax charges, leading to an 8.79% stock drop on October 7, 2026. Finally, on October 10, 2026, Wall Street Zen upgraded Azenta's stock rating from 'hold' to 'buy'.
